The Biomedical Advanced Research and Development Authority (BARDA) terminated 22 grants supporting mRNA vaccine development, resulting in withdrawal of nearly $500 million in federal funding. This funding pullback, reportedly influenced by concerns over mRNA technology’s safety, efficacy, and public trust, has heightened investor wariness toward mRNA vaccine projects. NIH Director Jay Bhattacharya cited lack of public confidence as a key factor in concluding the platform is no longer viable for vaccine development, though therapies employing mRNA for treatment indications remain unaffected. The move marks a significant shift in U.S. government support amid ongoing debates about mRNA vaccine acceptance.